Q4 a minor blip in Biocon's growth story, recovery expected in Q1FY21

Biocon’s revenue growth, at just 3 per cent for the March quarter (Q4), as compared to 13-30 per cent in the first three quarters of FY20, was largely because of the Covid-19-led supply disruption. The biologics segment (biosimilars), which has driven Biocon’s performance for seven straight quarters, declined 21 per cent year-on-year (YoY) in Q4 as the supply scheduled for the end of the quarter could not be completed. For the full year, however, biologics (30 per cent of revenues) still grew by 29 per cent over the previous year. Christiane Hamacher, CEO & managing director,.....

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel
Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.